Apreo Health Secures $130M Series B Funding to Transform Emphysema Treatment with Innovative Airway Scaffold Solutions

Apreo Health is thrilled to announce a remarkable funding milestone, having raised $130,000,000 to accelerate the development of its groundbreaking clinical-stage solutions for patients suffering from severe emphysema, an advanced form of Chronic Obstructive Pulmonary Disease (COPD). This significant capital injection underscores the strong confidence investors have in Apreo Health’s mission to restore health and improve quality of life for patients facing debilitating respiratory conditions. Headquartered in Menlo Park, CA, the company is poised to utilize these funds to further advance its pioneering Apreo BREATHE Airway Scaffold, an investigational implant specifically designed to gently release trapped air in hyper-inflated lungs, thereby addressing one of the most critical aspects of emphysema management. Given that COPD was the second leading cause of death in the United States in 2018 and with over 8,000 emphysema-related deaths recorded in 2023, there is an urgent need for innovative treatments that can offer a tangible difference in patient outcomes. The new funding will enable Apreo Health to enhance its clinical investigations, expand research and development operations, and refine its device technology under strict Federal investigational guidelines. By bridging the gaps between cutting-edge medical device innovation and critical patient care needs, Apreo Health reaffirms its commitment to scientific excellence, integrity, and patient well-being. This landmark funding round not only fuels the continued progress of the Apreo BREATHE Airway Scaffold but also marks a transformative step towards establishing a new standard of care for lung disease sufferers across the country.